PD-1 and BTLA and CD8+ T-cell "exhaustion" in cancer "Exercising" an alternative viewpoint

OncoImmunology

Volumn 1, Issue 5, 2012, Pages 735-738

  Haymaker, Cara ^a   Wu, Richard ^a,b   Bernatchez, Chantale ^a   Radvanyi, Laszlo ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

BTLA; Cancer; CD8+ T cells; Exhaustion; PD 1; Tumor infiltrating lymphocytes

Indexed keywords

BTLA PROTEIN; CELL MARKER; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

EID: 84875158548     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20823     Document Type: Article

References (20)

1. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003; 77:4911-27; PMID:12663797; http://dx.doi.org/10.1128/JVI.77.8.4911-4927.2003
2. Youngblood B, Wherry EJ, Ahmed R. Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells. Curr Opin HIV AIDS 2012; 7:50-7; PMID:22134341; http://dx.doi.org/10.1097/COH.0b013e32834ddcf2
3. Angelosanto JM, Wherry EJ. Transcription factor regulation of CD8+ T-cell memory and exhaustion. Immunol Rev 2010; 236:167-75; PMID:20636816; http://dx.doi.org/10.1111/j.1600-065X.2010.00927.x
4. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114:1537-44; PMID: 19423728; http://dx.doi.org/10.1182/blood-2008-12-195792
5. Baitsch L, Baumgaertner P, Devêvre E, Raghav SK, Legat A, Barba L, et al. Exhaustion of tumor-specific CD8? T cells in metastases from melanoma patients. J Clin Invest 2011; 121:2350-60; PMID:21555851; http://dx.doi.org/10.1172/JCI46102
6. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439:682-7; PMID:16382236; http://dx.doi.org/10.1038/nature04444
7. Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson L, Livingston S, McMahon BJ, et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol 2009; 83:9122-30; PMID:19587053; http://dx.doi.org/10.1128/JVI.00639-09
8. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207-12; PMID:22236695; http://dx.doi.org/10.1016/j.coi.2011.12.009
9. Duraiswamy J, Ibegbu CC, Masopust D, Miller JD, Araki K, Doho GH, et al. Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. J Immunol 2011; 186:4200-12; PMID:21383243; http://dx.doi.org/10.4049/jimmunol.1001783
10. Derré L, Rivals JP, Jandus C, Pastor S, Rimoldi D, Romero P, et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 2010; 120:157-67; PMID:20038811; http://dx.doi.org/10.1172/JCI40070
11. Youngblood B, Oestreich KJ, Ha SJ, Duraiswamy J, Akondy RS, West EE, et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity 2011; 35:400-12; PMID:21943489; http://dx.doi.org/10.1016/j.immuni.2011.06.015
12. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4; PMID:12242449; http://dx.doi.org/10.1126/science.1076514
13. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116
14. Wu RFM-A, Forget M-A, Chacon J, Bernatchez C, Haymaker C, Chen JQ, et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 2012; 18:160-75; PMID:22453018; http://dx.doi.org/10.1097/PPO.0b013e31824d4465
15. Schwartz RH. T cell anergy. Annu Rev Immunol 2003; 21:305-34; PMID:12471050; http://dx.doi.org/10.1146/annurev.immunol.21.120601.141110
16. Krönig H, Julia Falchner K, Odendahl M, Brackertz B, Conrad H, Muck D, et al. PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease. Int J Cancer 2012; 130:2327-36; PMID:21717461; http://dx.doi.org/10.1002/ijc.26272
17. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37.
18. Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 2012; 72:887-96; PMID:22205715; http://dx.doi.org/10.1158/0008-5472.CAN-11-2637
19. Baitsch L, Legat A, Barba L, Fuertes Marraco SA, Rivals JP, Baumgaertner P, et al. Extended coexpression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One 2012; 7: e30852; PMID:22347406; http://dx.doi.org/10.1371/journal.pone.0030852
20. Sakthivel P, Gereke M, Bruder D. Therapeutic intervention in cancer and chronic viral infections: antibody mediated manipulation of PD-1/PD-L1 interaction. Rev Recent Clin Trials 2012; 7:10-23; PMID:22023178; http://dx.doi.org/10.2174/15748871279936326